Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with select advanced hematologic malignancies who are refractory, resistant or intolerant to prior therapies for monotherapy cohort.~* Patients with AML or High-Risk MDS who are newly diagnosed and previously untreated for combination cohort.~* Patients with AML who are newly diagnosed and previously untreated for azacitidine combination cohort.~* ECOG \[Eastern Cooperative Oncology Group\] performance status 0 to 2~* Adequate organ function~Exclusion Criteria:~* Patients with active CNS disease~* Patient with active malignancy with the exception of basal cell carcinoma, non melanoma skin cancer, carcinoma in situ cervical~* Patient has an active, life threatening or clinically significant uncontrolled systemic infection

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monotherapy Cohort (Type: EXPERIMENTAL): PF-04449913 Monotherapy
- Combination Cohort 1 (Type: EXPERIMENTAL): PF-04449913 in combination with low dose ARA-C (LDAC)
- Combination Cohort 2 (Type: EXPERIMENTAL): PF-04449913 in combination with intensive chemotherapy: PF-04449913 administered continuously for 28 days. Daunorubicin given using 60 mg/m2 for 3-days together with cytarabine 100 mg/m2 on days 1 through 7 followed by cytarabine 1g/m2 on days 1, 3, and 5 during 2-4 cycles of consolidation therapy.
- Azacitidine Combination Cohort (Type: EXPERIMENTAL): PF-04449913 in combination with azacitidine
- Continuation Cohort (Type: EXPERIMENTAL): PF-04449913 Monotherapy for one patient rolled-over from another trial in the same project.
- Expansion Cohort of LDAC Combination for Efficacy (Type: EXPERIMENTAL): PF-04449913 in combination with LDAC to evaluate efficacy

Based on this trial design, predict the completion outcome and termination type (if applicable).